Lobular Breast Cancer Alliance Inc.

New LBCA Brochure! We have created a new brochure with a basic overview of ILC, its key features, information on imaging, a list of publications, the resources LBCA provides and more. The brochure is available in both a digital version to share online and as a download to print in 16 languages. Please share this brochure with anyone you think might benefit! https://lnkd.in/eNCCDdjN #LobularBreastCancer #LBCAResources

It's FAQ Friday, when we post a Frequently Asked Question about ILC and answer from our FAQs developed with the input of LBCA scientific advisory board members. This week's question is "What are the different subtypes and variants of LCIS?" See the answer below and read the rest of our FAQs here: https://lnkd.in/eSzUPuMH #LobularBreastCancer #ILCFAQs

UK Lobular Breast Cancer patients have the opportunity to help change breast cancer guidelines in the UK to get the most effective treatments for Lobular patients by completing Lobular Breast Cancer UK's patient survey. Currently, Lobular Breast Cancer is not recognized as a distinct disease in the UK NICE and SIGN guidelines. In response to patient demand, Lobular Breast Cancer UK has launched a campaign to change these guidelines. If you live in the UK and would like to complete the survey, please click here: https://lnkd.in/eUtxhM7S

LBCA has launched its second Local Advocacy Team, or LAT, for patients with ILC, in Washington, D.C., Maryland and Virginia. LBCA’s Local Advocacy Team Coordinator Kathleen Moss recently interviewed the newest organizers, LAT Ambassadors, Brenda Sulick and Jeanette Brown, to discuss their new LATDMV: D.C., Maryland & Virginia. Watch the interview here: https://lnkd.in/eY2fPpRT #lobularbreastcancer #LBCALAT #ilcadvocacy

It's FAQ Friday, when we post a Frequently Asked Question about ILC and answer from our FAQs developed with the input of LBCA scientific advisory board members. This week's question is "What are atypical lobular hyperplasia (ALH) and lobular carcinoma in-situ (LCIS)?" See the answer below and read the rest of our FAQs here: https://lnkd.in/eSzUPuMH #LobularBreastCancer #ILCFAQs

LBCA Scientific Advisory Board Chair, Dr. Jason Mouabbi, recently presented a research poster on invasive lobular carcinoma (ILC) at the American Society of Clinical Oncology (ASCO) annual meeting, one of the most significant gatherings of oncology professionals in the world. Dr. Mouabbi’s latest research reveals an evaluation approach that could lead to the development of personalized therapeutic strategies for ILC. See the poster and full abstract here: https://lnkd.in/ec7HUxcn #lobularbreastcancer #ilcresearch

Recently LBCA held a Lobular Breast Cancer Chat: Biomarkers as tools in ILC. In this 45-minute Chat, LBCA Scientific Advisory Board member Dr. Peter Simpson and his colleague Dr. Amy McCart Reed from the University of Queensland discussed biomarkers and their importance in ILC research. Topics covered include how biomarkers aid in research, the different types, ongoing discoveries and how they predict treatment benefit and prognosis. Watch the full presentation here https://lnkd.in/eHKfmRjU #lobularbreastcancer #ilcresearch

Meet Lizzie and hear about her journey to an invasive lobular carcinoma (ILC) diagnosis in 2020 after finding a lump, how COVID affected her treatment, and how volunteering to help other patients led her to find LBCA. Read her full story here: https://lnkd.in/eTQEiiJg #lobularbreastcancer #ilcstories

FAQ Friday! Each Friday we post a Frequently Asked Question about ILC and answer from our FAQs developed with the input of LBCA scientific advisory board members. This week's question is "What is invasive (or infiltrating) lobular carcinoma (ILC) and why is it unique?" See the answer below and read the rest of our FAQs here: https://lnkd.in/eSzUPuMH #LobularBreastCancer #ILCFAQs

Please help LBCA and take our survey! As LBCA continues to grow in pursuit of our mission, we seek feedback each year about how we are doing from everyone who uses our resources. We have prepared a survey to solicit your feedback anonymously, organized by our goals and activities in support of our mission, followed by a few questions about you to help us understand better your input. The survey takes 5 -10 minutes to complete and will close at 5pm on July 19th, you can take the survey here: https://lnkd.in/edJz-tnR